[
  {
    "ts": null,
    "headline": "Cytokinetics Stock Jumps. The Biotech’s Heart Drug Wows.",
    "summary": "Trial results for aficamten were presented to cardiologists over the weekend. One analyst said the drug could be “best-in-class therapy.”",
    "url": "https://finnhub.io/api/news?id=12396178285283ce76db31cdc54fdededcd047669e8bb0c398538f23d8cadd07",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756829340,
      "headline": "Cytokinetics Stock Jumps. The Biotech’s Heart Drug Wows.",
      "id": 136613299,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Trial results for aficamten were presented to cardiologists over the weekend. One analyst said the drug could be “best-in-class therapy.”",
      "url": "https://finnhub.io/api/news?id=12396178285283ce76db31cdc54fdededcd047669e8bb0c398538f23d8cadd07"
    }
  },
  {
    "ts": null,
    "headline": "Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?",
    "summary": "Bristol Myers expects mid to high-single-digit sales growth for Opdivo and Qvantig in 2025 as approvals and launches gain momentum.",
    "url": "https://finnhub.io/api/news?id=217ed689d8cfa7cb2bf09d2dc5295e9d583bbb676c3c402b7e32aa6a6abb4080",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756825800,
      "headline": "Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?",
      "id": 136613057,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers expects mid to high-single-digit sales growth for Opdivo and Qvantig in 2025 as approvals and launches gain momentum.",
      "url": "https://finnhub.io/api/news?id=217ed689d8cfa7cb2bf09d2dc5295e9d583bbb676c3c402b7e32aa6a6abb4080"
    }
  },
  {
    "ts": null,
    "headline": "SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Non-Small Cell Lung Cancer at WCLC Congress 2025",
    "summary": "SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced that two abstracts for iza-bren (izalontamab brengitecan), a potentially first-in-class EGFRxHER3 bispecific antibody drug conjugate (ADC), will be presented at the World Conference on Lung Cancer (WCLC) 2025 Annual Meeting taking place September 6 – 9 in Barcelona, Spain. Iza-bren is jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive license agreement in territories o",
    "url": "https://finnhub.io/api/news?id=26385552ac46aa60d0ee76962a288b44e24a7e2ef0a5f863f201ae693d920092",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756818000,
      "headline": "SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Non-Small Cell Lung Cancer at WCLC Congress 2025",
      "id": 136604367,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced that two abstracts for iza-bren (izalontamab brengitecan), a potentially first-in-class EGFRxHER3 bispecific antibody drug conjugate (ADC), will be presented at the World Conference on Lung Cancer (WCLC) 2025 Annual Meeting taking place September 6 – 9 in Barcelona, Spain. Iza-bren is jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive license agreement in territories o",
      "url": "https://finnhub.io/api/news?id=26385552ac46aa60d0ee76962a288b44e24a7e2ef0a5f863f201ae693d920092"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company (BMY) Launches $300M Immunology Spinout with Bain Capital",
    "summary": "We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Bristol-Myers Squibb Company stands eighth among them. Bristol-Myers Squibb Company (NYSE:BMY), a global biopharma leader, is making bold moves to strengthen its immunology presence through strategic partnerships and a growing pipeline. In July 2025, the company announced a […]",
    "url": "https://finnhub.io/api/news?id=753f03910e49f08203e10b82f590eb72d803a24ffe65e741ff782e7060d83cca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756801764,
      "headline": "Bristol-Myers Squibb Company (BMY) Launches $300M Immunology Spinout with Bain Capital",
      "id": 136604368,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Bristol-Myers Squibb Company stands eighth among them. Bristol-Myers Squibb Company (NYSE:BMY), a global biopharma leader, is making bold moves to strengthen its immunology presence through strategic partnerships and a growing pipeline. In July 2025, the company announced a […]",
      "url": "https://finnhub.io/api/news?id=753f03910e49f08203e10b82f590eb72d803a24ffe65e741ff782e7060d83cca"
    }
  }
]